Immunology and Biotherapies
13.6K views | +2 today
Follow
 
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
onto Immunology and Biotherapies
Scoop.it!

CAR T-Cell Therapies: Positive Early Results - Clinical Oncology News

CAR T-Cell Therapies: Positive Early Results - Clinical Oncology News | Immunology and Biotherapies | Scoop.it
CAR T-Cell Therapies: Positive Early Results
Clinical Oncology News
Subsequent use of tocilizumab (Actemra, Hoffman-La Roche), an interleukin-6 inhibitor, reduced these adverse events without exerting any apparent effect on outcomes.

Via Krishan Maggon
more...
No comment yet.
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert C FAURE
Scoop.it!

Resources for DIU Immunologie et Biothérapies

DIU Immunologie et Biotherapies is a french diploma associating many french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular

Gilbert C FAURE's insight:

We choose Scoop.it as the best curation tool to collect, select, comment informations flowing on the web in this rapidly evolving theme to keep teachers abreast of scientific knowledge and help students surf the wave...

Feel free to be a follower!

 

If you are interested

in Immunology also use http://www.scoop.it/t/immunology

in Mucosal Immunity http://www.scoop.it/t/mucosal-immunity

in Flow Cytometry and Cytomics http://www.scoop.it/t/from-flow-cytometry-to-cytomics

in Allergy an Clinical Immunology http://www.scoop.it/t/allergy-and-clinical-immunology

in Autoimmunity http://www.scoop.it/t/autoimmunity

 

For further informantions on Immune monitoring of Immune therapies, go to

http://www.scoop.it/t/immune-monitoring-1

by MdC

 

Looking for cancer applications inside this topic, use

http://www.scoop.it/t/immunology-and-biotherapies?q=cancer

 

Looking for cytokines and chemokines, use

http://www.scoop.it/t/cytokines-et-chimiokines

 

more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Titanic clash over CRISPR patents turns ugly

Titanic clash over CRISPR patents turns ugly | Immunology and Biotherapies | Scoop.it
Accusations of impropriety feature in escalating dispute.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Medical Research Council launches disease compounds research library - PMLiVE

Medical Research Council launches disease compounds research library - PMLiVE | Immunology and Biotherapies | Scoop.it
Teams up
with AZ, GSK, Janssen, Pfizer, Takeda and UCB
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Building Better Bones with Biologics — A New Approach to Osteoporosis? — NEJM

Building Better Bones with Biologics — A New Approach to Osteoporosis? — NEJM | Immunology and Biotherapies | Scoop.it
Editorial from The New England Journal of Medicine — Building Better Bones with Biologics — A New Approach to Osteoporosis?
more...
No comment yet.
Suggested by Société Francaise d'Immunologie
Scoop.it!

Efficient production and enhanced tumor delivery of engineered extracellular vesicles | Exosome RNA

Efficient production and enhanced tumor delivery of engineered extracellular vesicles | Exosome RNA | Immunology and Biotherapies | Scoop.it
Extracellular vesicles (EV), including exosomes and microvesicles, are nano-sized intercellular communication vehicles that participate in a multitude of
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Inner Ear Regeneration: Hearing Loss, Tinnitus and Vertigo

Inner Ear Regeneration: Hearing Loss, Tinnitus and Vertigo | Immunology and Biotherapies | Scoop.it
Advanced Rejuvenation is using cutting edge therapies to stimulate hair cell (inner ear) regeneration through stem cell treatment, laser therapy and growth factor injections
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Toward Preventing Transplant Rejection with Immunologically Matched Stem Cells | The Scientist Magazine®

Toward Preventing Transplant Rejection with Immunologically Matched Stem Cells | The Scientist Magazine® | Immunology and Biotherapies | Scoop.it
Matching the immunological characteristics of donor retinal cells to those of the recipient can reduce the chance of rejection.
more...
No comment yet.
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

9th Workshop on Monoclonal Antibodies

9th Workshop on Monoclonal Antibodies | Immunology and Biotherapies | Scoop.it
RT @LonzaGroup: #LonzaDrugProduct expert is speaking at the PDA antibody workshop next week. For info: https://t.co/c6XJl5nrxL https://t.c
Via Krishan Maggon
more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

Agenda at a Glance - CAR-TCR Summit

Agenda at a Glance - CAR-TCR Summit | Immunology and Biotherapies | Scoop.it
Accelerate translation, clinical development and commercialization of the next generation of CAR-T & TCR cellular immunotherapies.
Via Krishan Maggon
more...
No comment yet.
Rescooped by Gilbert C FAURE from Herbovie
Scoop.it!

Theradiag ouvre son capital à HOB Biotech, son partenaire chinois

Theradiag ouvre son capital à HOB Biotech, son partenaire chinois | Immunology and Biotherapies | Scoop.it
Si les apports financiers chinois aux biotech française

Via herbovie
more...
No comment yet.
Rescooped by Gilbert C FAURE from Biotech Pharma Innovation in Immuno-Oncology & beyond. Cancer - Immunology - Immunotherapy.
Scoop.it!

Resources & Videos - 2016 Biosimilars Trends Report | 

Resources & Videos - 2016 Biosimilars Trends Report |  | Immunology and Biotherapies | Scoop.it
The biologics landscape is evolving and biosimilars are a growing part of the conversation. Biosimilars bring anticipated savings, and also some additional questions. The 3rd edition of the Trends in Biosimilars Report strives to provide timely and useful information on some of the crucial biosimilar issues that the broader healthcare community is grappling with today. The report provides insights from key stakeholders, including highly experienced medical and pharmacy directors representing a broad mix of managed care organizations throughout the U.S., as well as employer and benefit design consultants.

Via Dominique Blanchard
more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

Development of Novel Immunotherapies for Multiple Myeloma

Development of Novel Immunotherapies for Multiple Myeloma | Immunology and Biotherapies | Scoop.it
Multiple myeloma (MM) is a disorder of terminally differentiated plasma cells characterized by clonal expansion in the bone marrow (BM). It is the second-most common hematologic malignancy. Despite significant advances in therapeutic strategies, MM remains a predominantly incurable disease emphasizing the need for the development of new treatment regimens. Immunotherapy is a promising treatment modality to circumvent challenges in the management of MM. Many novel immunotherapy strategies, such as adoptive cell therapy and monoclonal antibodies, are currently under investigation in clinical trials, with some already demonstrating a positive impact on patient survival. In this review, we will summarize the current standards of care and discuss major new approaches in immunotherapy for MM. 

Keywords: multiple myeloma; monoclonal antibodies; stem cell transplantation; CAR-T cell therapy

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, September 8, 8:23 PM
Int. J. Mol. Sci. 2016, 17(9), 1506; doi: 10.3390/ijms17091506 Review 
Development of Novel Immunotherapies for Multiple Myeloma 

Ensaf M. Al-Hujaily 1, Robyn A. A. Oldham 1,2, Parameswaran Hari 3 and Jeffrey A. Medin
Scooped by Gilbert C FAURE
Scoop.it!

Cellectis, la pépite française anticancer

Cellectis, la pépite française anticancer | Immunology and Biotherapies | Scoop.it
La biotech fondée par André Choulika est à la pointe des thérapies géniques contre le cancer. Une maladie don
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Comparison of infliximab drug measurement across three commercially available ELISA kits

if your university is connected
Pathology Volume 48, Issue 6, October 2016, Pages 608–612
Gilbert C FAURE's insight:
Summary The monitoring of infliximab drug levels aids in the management of several autoimmune diseases, notably inflammatory bowel disease. Several commercial kits are now available and approved by the Therapeutic Goods Administration (TGA) for the measurement of infliximab levels, but there have been limited verification or comparison studies to date. Finding an assay that most accurately measures infliximab is essential for optimal drug titration and patient management. We performed this study to compare the performance of the Grifols Promonitor, Theradiag Lisatracker and R-Biopharm Ridascreen enzyme linked immunosorbent assay (ELISA) kits. Preparations of serum containing known concentrations of infliximab were assayed using each kit, including in the presence of interference from anti-infliximab antibodies, autoantibodies and other biological agents. The Lisatracker kit provided the most accurate determination of infliximab drug levels, however it yielded false positive results at low concentrations of infliximab. The average coefficients of variation (CVs) for the kits were 8% for Lisatracker, 5% for Ridascreen and 11% for Grifols. Infliximab measurements across all kits were affected by interference from antibodies to infliximab (ATI). This study identified the Lisatracker kit as the most accurate in quantifying infliximab levels, although it was limited by false positive results at low concentrations of infliximab as well as interference from ATI. This has important implications for the monitoring and management of patients receiving infliximab therapy.
more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

F1000Research Article: Recent advances in T-cell engineering for use in immunotherapy.

F1000Research Article: Recent advances in T-cell engineering for use in immunotherapy. | Immunology and Biotherapies | Scoop.it
Read the latest article version by Preeti Sharma, David M. Kranz, at F1000Research.

Abstract Adoptive T-cell therapies have shown exceptional promise in the treatment of cancer, especially B-cell malignancies. Two distinct strategies have been used to redirect the activity of ex vivo engineered T cells. In one case, the well-known ability of the T-cell receptor (TCR) to recognize a specific peptide bound to a major histocompatibility complex molecule has been exploited by introducing a TCR against a cancer-associated peptide/human leukocyte antigen complex. In the other strategy, synthetic constructs called chimeric antigen receptors (CARs) that contain antibody variable domains (single-chain fragments variable) and signaling domains have been introduced into T cells. Whereas many reviews have described these two approaches, this review focuses on a few recent advances of significant interest. The early success of CARs has been followed by questions about optimal configurations of these synthetic constructs, especially for efficacy against solid tumors. Among the many features that are important, the dimensions and stoichiometries of CAR/antigen complexes at the synapse have recently begun to be appreciated. In TCR-mediated approaches, recent evidence that mutated peptides (neoantigens) serve as targets for endogenous T-cell responses suggests that these neoantigens may also provide new opportunities for adoptive T-cell therapies with TCRs.

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, September 20, 8:08 AM
Sharma P and Kranz DM. Recent advances in T-cell engineering for use in immunotherapy [version 1; referees: 3 approved]. F1000Research 2016, 5(F1000 Faculty Rev):2344 (doi: 10.12688/f1000research.9073.1)
Scooped by Gilbert C FAURE
Scoop.it!

Regulatory T Cell-based Therapies for Autoimmunity - Benjamine Arellano - Discovery Medicine

Regulatory T Cell-based Therapies for Autoimmunity - Benjamine Arellano - Discovery Medicine | Immunology and Biotherapies | Scoop.it
Autoimmune disorders are long-term diseases that adversely affect the quality of life for patients, and they are one of the top ten leading causes of death. While each autoimmune disorder is unique, they all are caused by a breakdown of .
more...
No comment yet.
Suggested by Société Francaise d'Immunologie
Scoop.it!

FASEB > Resources for the Public > Breakthroughs and Horizons in Bioscience > The Immune System and Vaccines

FASEB > Resources for the Public > Breakthroughs and Horizons in Bioscience > The Immune System and Vaccines | Immunology and Biotherapies | Scoop.it
Click here to edit the content
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Cancer Immunotherapy At A Crossroads

Cancer Immunotherapy At A Crossroads | Immunology and Biotherapies | Scoop.it
Doctors can now marshal patients' immune systems to fight some cancers. Yet many people don't respond to immunotherapy, and the costs of treatment can be astronomical.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ

more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Yale Cancer Center Researchers Identify New T cell Subsets with Potential to Improve Cellular Therapy for Cancer

Yale Cancer Center Researchers Identify New T cell Subsets with Potential to Improve Cellular Therapy for Cancer | Immunology and Biotherapies | Scoop.it
A Yale Cancer Center research team has identified that two genes, NR4A1 and ABC transporters, mark a distinct subset of quiescent T cells within human tissues, and have developed methods to mobilize them into circulation for potential application...
more...
No comment yet.
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

FDA Fast Track Designation for Angimmune’s Investigational Cutaneous T-cell Lymphoma Disease Treatment Resimmune®/A-dmDT390-bisFv(UCHT1) 

FDA Fast Track Designation for Angimmune’s Investigational Cutaneous T-cell Lymphoma Disease Treatment  Resimmune®/A-dmDT390-bisFv(UCHT1)  | Immunology and Biotherapies | Scoop.it
FDA Fast Track Granted to Angimmune


ROCKVILLE, MD, September 9, 2016 – Today Angimmune announced that A-dmDT390-bisFv(UCHT1) or Resimmune®, its investigational treatment for cutaneous T-cell lymphoma (CTCL), was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). The designation is for the most common form of cutaneous T-cell lymphoma, mycosis fungoides.

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, September 14, 6:03 PM
Resimmune® is an Anti-CD3 Immunotoxin that can be used to induce anti-tumor CD8 central memory T cell expansion following T cell depletion during homeostatic proliferation.
Scooped by Gilbert C FAURE
Scoop.it!

A second chance for telomerase reverse transcriptase in anticancer immunotherapy : Nature Reviews Clinical Oncology : Nature Research

more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

JCI - Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells

The adoptive transfer of clinical-grade T cells genetically modified with retrovirus or lentivirus to express a chimeric antigen receptor (CAR) has been shown in clinical trials to lyse CD19+ tumor cells (1–10).
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

A “Trojan horse” bispecific antibody strategy for broad protection against ebolaviruses

A “Trojan horse” bispecific antibody strategy for broad protection against ebolaviruses | Immunology and Biotherapies | Scoop.it
There is an urgent need for monoclonal antibody (mAb) therapies that broadly protect against Ebola virus and other filoviruses. The conserved, essential interaction between the filovirus glycoprotein, GP, and its entry receptor Niemann-Pick C1 (NPC1) provides an attractive target for such mAbs, but is shielded by multiple mechanisms, including physical sequestration in late endosomes. Here, we describe a bispecific antibody strategy to target this interaction, in which mAbs specific for NPC1 or the GP receptor-binding site are coupled to a mAb against a conserved, surface-exposed GP epitope. Bispecific antibodies, but not parent mAbs, neutralized all known ebolaviruses by coopting viral particles themselves for endosomal delivery, and conferred post-exposure protection against multiple ebolaviruses in mice. Such ‘Trojan horse’ bispecific antibodies have potential as broad anti-filovirus immunotherapeutics.
Gilbert C FAURE's insight:
bispecific antibodies!
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

New Anticancer Drugs Associated With Large Increases In Costs And Life Expectancy

New Anticancer Drugs Associated With Large Increases In Costs And Life Expectancy | Immunology and Biotherapies | Scoop.it
more...
No comment yet.